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Discussion
In this series of case 
studies the Advazorb® 
range was found 
to provide an ideal 
environment for healing 
to occur, as it is able to 
rapidly control moderate 
to high levels of exudate, 
preventing maceration 
even under compression.  
Advazorb Silfix® soft 
silicone is designed to minimise pain and trauma on dressing 
change, ensuring that surrounding fragile skin and newly 
formed granulation tissue is protected. 
Conclusion
The Advazorb® extensive dressing range is highly acceptable 
to practitioners and patients alike and has found to be 
clinically effective, in addition this presents an opportunity to 
significantly reduce costs without compromising quality of 
care.
an increased bacterial load. 
Advazorb® non adhesive 
foam dressing was applied 
as a primary dressing due 
to it’s rapid and highly 
absorbent properties and 
it’s highly conformable 
nature, ideal to fit around 
difficult areas like the 
malleolus. Four weeks later 
healing was evident, slough 
had been debrided leaving 
a healthy ulcer which had reduced in size along with the levels 
of exudate.
Case Study 3
Mr B presented acutely with 
an ulcerated painful left great 
toe, present for 2 weeks, 
two areas of ulceration 
were evident which were 
highly exudating. It was 
being dressed with a non 
adherent dressing, but these 
were failing to manage the 
levels of exudate, resulting 
in extensive maceration 
(Fig 5). Mr B had no past medical history, but blood glucose 
testing revealed elevated blood sugar levels and he was later 
diagnosed with diabetes. Antibiotics were commenced and the 
ulcer was dressed with Advazorb® non adherent foam, due 
to it’s highly absorbent properties and has added benefits of 
being highly conformable and additionally can be cut to shape 
to ensure comfortable and secure dressing of difficult areas 
such as the toes.
Only 48 hours later there was significant improvement 
evident, due to the rapid fluid absorbency of Advazorb® 
and the fluid retention properties. The surrounding skin 
maceration was completely resolved (Fig 6), infection was 
reducing and healing of the ulcerated areas were evident.
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Introduction
Effective management of wound exudate is key to 
promoting successful wound healing (White and 
Cutting, 2006). Foam dressings are frequently used to 
effectively manage exudate levels to promote wound 
healing and prevent maceration, but such dressings 
present a costly burden to the NHS.  In 2010 wound 
dressings accounted for £116 million of prescribing 
costs within Primary Care in England, with foam 
dressings being one of the most commonly prescribed 
wound management products, accounting for 19% 
of the total £116 million annual spend (National 
Prescribing Centre, 2010).  Advazorb® (Advancis 
Medical) is a comprehensive range of foam dressings 
presented in non adhesive and atraumatic silicone 
adhesives, which could provide the opportunity to 
reduce costs, without compromising quality of care.
Method
A small series of case studies were conducted using 
Advazorb® foam dressings on a variety of wounds with 
varying aetiologies.
Results
Case Study 1
A patient with a painful 
ulceration to the leg, 
present for 3 months.  The 
ulcer was superficial in 
depth with approximately 
90% dehydrated slough 
visible, which was 
turning into eschar (Fig 
1).  Surrounding skin 
appeared discoloured and 
fragile.  On assessment full 
complement of pulses, Ankle Brachial Pressure Index (ABPI) 
of 0.95, with normal triphasic Doppler tone, indicating no 
peripheral arterial disease. 
The ulcer was diagnosed 
as being venous in origin 
and was commenced 
on 4 layer compression 
bandaging, to reduce the 
venous hypertension and 
promote healing.  Activon 
Tulle® (Advancis Medical) 
dressings were used to 
rehydrate the slough and 
eschar. This was topped with Advazorb Silfix® soft silicone 
faced adhesive foam dressings, to ensure the wound bed was 
kept moist, but simultaneously coping with any increase in 
exudate caused by the honey rehydrating the wound bed. 
Four weeks reduced it in size (Fig 2), the wound bed showed 
100% granulation tissue and surrounding skin appeared healthy. 
Activon Tulle® was discontinued and Advazorb Silfix® was used 
as primary dressing under compression bandaging. Four weeks 
later the wound fully healed.
Case Study 2
Mr P presented with a 
non healing ulceration, 
ongoing for 4 months, 
previously treated with 
topical silver dressings. 
There had been little 
progress so he was 
referred to the leg ulcer 
clinic. An examination 
revealed palpable 
peripheral pulses and ABPI of 0.75, below recommended 
guidance for full strength compression therapy.  The ulcer 
showed superficial slough, with little evidence of wound 
edge advancement, exudate levels moderate to high with 
mild oedema to limb (Fig 3).  Mr P commenced on modified 
compression to reduce the oedema and promote healing. 
Silver dressings were discontinued as there was no evidence of 
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